Search Results

You are looking at 171 - 180 of 388 items for :

  • Refine by Access: All x
Clear All
Full access

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Peter F. Coccia, Alberto S. Pappo, Lynda Beaupin, Virginia F. Borges, Scott C. Borinstein, Rashmi Chugh, Shira Dinner, Jeanelle Folbrecht, A. Lindsay Frazier, Robert Goldsby, Alexandra Gubin, Robert Hayashi, Mary S. Huang, Michael P. Link, John A. Livingston, Yousif Matloub, Frederick Millard, Kevin C. Oeffinger, Diane Puccetti, Damon Reed, Steven Robinson, Abby R. Rosenberg, Tara Sanft, Holly L. Spraker-Perlman, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Nicholas Yeager, Lisa A. Gurski, and Dorothy A. Shead

, fatigue, nausea, vomiting, mucositis, hair loss, infection, and myelosuppression are some of the acute side effects of chemotherapy. Reversible toxicities do not necessarily warrant dose reductions. See the NCCN Guidelines for Supportive Care (available at

Full access

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. Klempner, Jill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, and Lenora A. Pluchino

experienced a complete response, partial response, and stable disease. The most frequently reported grade 3 or higher adverse events were diarrhea (26.6%), fatigue (15.5%), nausea (20%), and vomiting (13.3%). In a retrospective study of 34 patients with HER2

Full access

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

Prithviraj Bose and Srdan Verstovsek

preclinically in MPN, both in vitro and in vivo, 50 , 51 and are clearly active in patients with PV and ET, but the chronic low-grade toxicities of these agents (eg, fatigue, diarrhea, nausea, myelosuppression) make them difficult to tolerate long-term. 52 – 54

Full access

Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations

Joshua K. Sabari, John V. Heymach, and Beth Sandy

-related adverse events occurring in ≥30% of patients were diarrhea (90% of patients; grade ≥3 in 21% of PPP and 16% of EXCLAIM cohort patients), rash (45%), paronychia (35%), decreased appetite (∼30%), nausea (∼30%), and dry skin (30%). Figure 3. Design and

Full access

Palliative Care

Michael H. Levy, Michael D. Adolph, Anthony Back, Susan Block, Shirley N. Codada, Shalini Dalal, Teresa L. Deshields, Elisabeth Dexter, Sydney M. Dy, Sara J. Knight, Sumathi Misra, Christine S. Ritchie, Todd M. Sauer, Thomas Smith, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Jay Thomas, Roma Tickoo, Susan G. Urba, Jamie H. Von Roenn, Joseph L. Weems, Sharon M. Weinstein, Deborah A. Freedman-Cass, and Mary Anne Bergman

the greatest need in patients with head and neck cancer, melanoma, and brain tumors. 3 More than one-third of patients with cancer in a large observational cohort study reported moderate to severe symptoms in most categories (pain, nausea, anxiety

Full access

Abstracts From the NCCN 2020 Virtual Annual Conference

that commonly may limit Ctx or require a dose modification (mouth sores, diarrhea, nausea, vomiting, rash, hand-foot syndrome, and neuropathy). Exact McNemar’s test was used to analyze agreement in reporting between patient and provider for each tox

Full access

Cancer-Related Fatigue, Version 2.2015

Ann M. Berger, Kathi Mooney, Amy Alvarez-Perez, William S. Breitbart, Kristen M. Carpenter, David Cella, Charles Cleeland, Efrat Dotan, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Catherine Jankowski, Thomas LeBlanc, Jennifer A. Ligibel, Elizabeth Trice Loggers, Belinda Mandrell, Barbara A. Murphy, Oxana Palesh, William F. Pirl, Steven C. Plaxe, Michelle B. Riba, Hope S. Rugo, Carolina Salvador, Lynne I. Wagner, Nina D. Wagner-Johnston, Finly J. Zachariah, Mary Anne Bergman, and Courtney Smith

has not been made in practice, despite conceptual differences. 19 , 20 Patients perceive fatigue to be the most distressing symptom associated with cancer and its treatment, more distressing even than pain or nausea and vomiting, which can generally

Full access

Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors

Sujata Narayanan and Pamela L. Kunz

analogues include nausea, abdominal Table 3 Summary of Completed Randomized Clinical Trials With Somatostatin Analogues cramps, diarrhea, steatorrhea, flatulence, hyperglycemia, and cholelithiasis/biliary sludging. Most of these symptoms are

Full access

Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic

Tanya M. Wildes, Derek L. Stirewalt, Bruno Medeiros, and Arti Hurria

have not been reported across all studies, and, in one report, older adults actually had less nausea than their younger counterparts (5% vs 18%; P =.007). 17 Table 1 Summary Conclusions on Currently Available Data on Auto-HCT and Allo-HCT in

Full access

Adolescent and Young Adult Oncology, Version 2.2014

Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead, and Hema Sundar

of nausea and vomiting have been used in pregnant women without any significant side effects. 55 , 70 , 71 The panel members acknowledged that management of cancer during pregnancy poses significant diagnostic and therapeutic challenges for both the